At a glance
ClinicalIndex Comparison RecordN/ACompleted· 408 enrolled
Drug / intervention
Antiviral Agentsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prognostic Relevance of Fatty Liver Disease for Patients With Chronic Hepatitis B
In Brief
An observational study evaluating Antiviral Agents for Fatty Liver and Chronic Hepatitis b. Completed, enrolled 408 participants across 1 site.
Detailed Summary
Fatty liver disease is increasingly recognized in patients with chronic hepatitis B (CHB). Whether concurrent fatty liver disease affects the long-term outcomes of CHB is unclear. The investigators performed a longitudinal study to investigate the prognostic relevance of concurrent fatty liver disease for patients with CHB receiving antiviral therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFatty Liver, Chronic Hepatitis b
CountriesThailand
Collaborators--
Timeline
N/ACompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2002
Primary CompletionDec 2020
Study CompletionDec 2021
First PostedApr 2022
TodayJul 2026
First PostedApr 7, 2022
Enrollment StartJan 1, 2002
Primary CompletionDec 31, 2020
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 19 yearsPosted 4.2 years ago
Interventions
Antiviral Agentsdrug
The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.